Sanguis et Cinis

EQS-News: Sangui BioTech International Inc.: - Sales of USD 41,029 in first quarter - For the first time, positive quarterly result in the company's history

Retrieved on: 
Friday, November 11, 2022

Sangui BioTech International Inc.: - Sales of USD 41,029 in first quarter - For the first time, positive quarterly result in the company's history

Key Points: 
  • Sangui BioTech International Inc.: - Sales of USD 41,029 in first quarter - For the first time, positive quarterly result in the company's history
    The issuer is solely responsible for the content of this announcement.
  • Operating expenses decreased USD 4,872 or 8% to USD 57,231 during the first quarter.
  • As a result of the above factors, the three-month operating loss decreased USD 27,341 to USD 16,202.
  • Compared to the previous year, in which a loss of USD 27,917 had occurred in the comparable period, the quarterly result improved by USD 52,851.

EQS-News: Sangui BioTech International Inc.: Increase in sales in the first quarter of 121% - Highest quarterly sales in the company's history

Retrieved on: 
Wednesday, October 12, 2022

Considering the effects from the exchange rate development of the US dollar to the Euro, the increase in license revenue is even 159%.

Key Points: 
  • Considering the effects from the exchange rate development of the US dollar to the Euro, the increase in license revenue is even 159%.
  • In the first quarter of the 2023 financial year, the highest license revenues have been achieved since the license agreement was concluded.
  • Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI).
  • Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group.

EQS-News: Sangui BioTech International Inc.: Sales of USD 69,190 in fiscal year 2022 - Reduction of the operating loss

Retrieved on: 
Thursday, September 29, 2022

Hamburg, September, 29 2022: In the fiscal year 2022 (01/07/2021 to 30/06/2022) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 69,190.

Key Points: 
  • Hamburg, September, 29 2022: In the fiscal year 2022 (01/07/2021 to 30/06/2022) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 69,190.
  • Due to increased revenues of the wound spray Granulox, the resulting royalty income of 2022 increased by 5% compared to previous year.
  • Operating expenses decreased USD 8,087 or 4% to USD 208,636.
  • As a result of the above factors, operating loss decreased USD 11,692 to USD 139,446.

DGAP-News: Sangui BioTech International Inc.: - Increase in sales in the first nine months of the year - Further reduction of the operating loss

Retrieved on: 
Tuesday, May 17, 2022

Hamburg, May 17 2022: In the first nine months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 58,686.

Key Points: 
  • Hamburg, May 17 2022: In the first nine months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 58,686.
  • Operating expenses decreased USD 12,412 or 8% to USD 150,381 during the first three quarters of the year.
  • As a result of the above factors, the nine-month operating loss decreased USD 19,344 to USD 91,695.
  • Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group.

DGAP-News: Sangui BioTech International Inc.: Significant increase in sales in the first half of the year - Further reduction of the operating loss

Retrieved on: 
Thursday, February 17, 2022

Hamburg, February 16 2022: In the first six months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 40,732.

Key Points: 
  • Hamburg, February 16 2022: In the first six months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 40,732.
  • Operating expenses decreased USD 9,309 or 8% to USD 103,977 during the first half year of the year.
  • As a result of the above factors, the six-month operating loss decreased USD 19,469 to USD 63,245.
  • Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group.

DGAP-News: Sangui BioTech International Inc.: - Sales of USD 18,560 in first quarter - Reduction of the operating loss

Retrieved on: 
Monday, November 15, 2021

Hamburg, November 15, 2021: In the first three months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 18,560.

Key Points: 
  • Hamburg, November 15, 2021: In the first three months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 18,560.
  • In the same period of the previous year the comparable revenue amounted to USD 19,880.
  • Operating expenses decreased USD 2,187 or 3% to USD 62,103 during the first quarter.
  • As a result of the above factors, the three month operating loss decreased USD 867 to USD 43,543.

DGAP-News: Sangui BioTech International Inc.: - Sales of USD 65,582 in fiscal year 2021 - Reduction of the operating loss

Retrieved on: 
Wednesday, September 29, 2021

Hamburg, September, 29 2021: In the fiscal year 2021 (01/07/2020 to 30/06/2021) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 65,582.

Key Points: 
  • Hamburg, September, 29 2021: In the fiscal year 2021 (01/07/2020 to 30/06/2021) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 65,582.
  • In the same period of the previous year the comparable revenue amounted to USD 28,915.
  • Due to increased revenues of the wound spray Granulox, the resulting royalty income of 2021 increased by 127% compared to previous year.
  • As operating expenses increased USD 6,414 or 3% to USD 216,723 during the period, operating loss decreased USD 30,256 to USD 151,138 from the prior year.